| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 04/02/2025 | 14:00 | GlobeNewswire Inc. | Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1 | NASDAQ:ELAB | PMGC Holdings Inc |
| 31/01/2025 | 22:19 | Edgar (US Regulatory) | Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors | NASDAQ:ELAB | PMGC Holdings Inc |
| 31/01/2025 | 16:33 | GlobeNewswire Inc. | PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fire Prevention Technology Companies | NASDAQ:ELAB | PMGC Holdings Inc |
| 30/01/2025 | 14:00 | GlobeNewswire Inc. | Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 | NASDAQ:ELAB | PMGC Holdings Inc |
| 28/01/2025 | 22:01 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ELAB | PMGC Holdings Inc |
| 27/01/2025 | 15:00 | GlobeNewswire Inc. | PMGC Holdings Inc. Announces $1.9 Million in Gross Proceeds from Warrant Inducement with Institutional Investors | NASDAQ:ELAB | PMGC Holdings Inc |
| 27/01/2025 | 12:03 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:ELAB | PMGC Holdings Inc |
| 24/01/2025 | 14:00 | GlobeNewswire Inc. | Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium | NASDAQ:ELAB | PMGC Holdings Inc |
| 16/01/2025 | 14:31 | GlobeNewswire Inc. | PMGC Holdings Inc. Announces Closing of Elevai Skincare Divestiture | NASDAQ:ELAB | PMGC Holdings Inc |
| 15/01/2025 | 15:30 | GlobeNewswire Inc. | PMGC Holdings Inc. Announces Name Change of Wholly Owned Subsidiaries | NASDAQ:ELAB | PMGC Holdings Inc |
| 02/01/2025 | 21:55 | GlobeNewswire Inc. | PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy | NASDAQ:ELAB | PMGC Holdings Inc |
| 02/01/2025 | 14:00 | GlobeNewswire Inc. | Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products | NASDAQ:ELAB | PMGC Holdings Inc |
| 21/12/2024 | 01:30 | GlobeNewswire Inc. | Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada | NASDAQ:ELAB | PMGC Holdings Inc |
| 20/12/2024 | 13:30 | GlobeNewswire Inc. | Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada | NASDAQ:ELAB | PMGC Holdings Inc |
| 09/12/2024 | 14:00 | GlobeNewswire Inc. | Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation | NASDAQ:ELAB | PMGC Holdings Inc |
| 06/12/2024 | 13:30 | GlobeNewswire Inc. | Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market | NASDAQ:ELAB | PMGC Holdings Inc |
| 04/12/2024 | 14:00 | GlobeNewswire Inc. | Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division | NASDAQ:ELAB | PMGC Holdings Inc |
| 25/11/2024 | 23:18 | Edgar (US Regulatory) | Form DEFR14C - Revised information statement materials, definitive | NASDAQ:ELAB | PMGC Holdings Inc |
| 23/11/2024 | 00:23 | GlobeNewswire Inc. | Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance | NASDAQ:ELAB | PMGC Holdings Inc |
| 22/11/2024 | 23:11 | Edgar (US Regulatory) | Form SC TO-I/A - Tender offer statement by Issuer: [Amend] | NASDAQ:ELAB | PMGC Holdings Inc |
| 22/11/2024 | 23:00 | GlobeNewswire Inc. | Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess | NASDAQ:ELAB | PMGC Holdings Inc |
| 22/11/2024 | 14:11 | Edgar (US Regulatory) | Form DEF 14C - Other definitive information statements | NASDAQ:ELAB | PMGC Holdings Inc |
| 14/11/2024 | 20:35 | GlobeNewswire Inc. | CORRECTION - Elevai Labs Inc. | NASDAQ:ELAB | PMGC Holdings Inc |
| 14/11/2024 | 15:08 | GlobeNewswire Inc. | Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update | NASDAQ:ELAB | PMGC Holdings Inc |
| 04/11/2024 | 23:45 | GlobeNewswire Inc. | Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange | NASDAQ:ELAB | PMGC Holdings Inc |
| 22/10/2024 | 15:54 | GlobeNewswire Inc. | Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity | NASDAQ:ELAB | PMGC Holdings Inc |
| 21/10/2024 | 13:30 | GlobeNewswire Inc. | Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity | NASDAQ:ELAB | PMGC Holdings Inc |
| 04/10/2024 | 23:26 | Edgar (US Regulatory) | Form SC TO-I - Tender offer statement by Issuer | NASDAQ:ELAB | PMGC Holdings Inc |
| 04/10/2024 | 23:08 | GlobeNewswire Inc. | Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock | NASDAQ:ELAB | PMGC Holdings Inc |
| 03/10/2024 | 21:45 | GlobeNewswire Inc. | REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations | NASDAQ:ELAB | PMGC Holdings Inc |
